Humanigen to Host Investor KOL Conference Call

• Conference call and webcast scheduled for Thursday, September 3 at 11:00 a.m. EDT

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (HGEN) (“Humanigen”), announced today that the Company will host an investor call and webcast to discuss the case-control lenzilumab data in COVID-19 patients published this week in Mayo Clinic Proceedings, including a discussion with the infectious disease expert and lead author of the study, Dr. Zelalem Temesgen, Professor of Medicine at Mayo Clinic, and provide corporate updates.

Humanigen will host the conference call and webcast Thursday, September 3, 2020 at 11:00 a.m. EDT. All stakeholders are invited to attend.

To participate on the conference call, please dial toll free (833) 714-0938 or toll number (778) 560-2680. The conference ID number is 1158096. A simultaneous webcast of the call and presentation can be accessed by visiting: https://event.on24.com/wcc/r/2626581/3E36D8F5A4B03E3030E7A0D438AF9AA1.

In addition, a replay of the webcast will be available on the company website for 30 days following the event. (Read more…)

More details on Humanigen’s programs in COVID-19 can be found on the company’s website at www.humanigen.com under the COVID-19 tab, and details of the US Phase III potential registration study can be found at clinicaltrials.gov using Identifier NCT04351152.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta^® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in the Company’s periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

Contacts

Media
Sean Leous

Westwicke, an ICR company

[email protected]
646-866-4012

Investors
Victoria Meissner, MD

Westwicke, an ICR company

[email protected]
646-677-1837